Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any advanced sleep phase syndrome in which the cause of the disease is a mutation in the PER3 gene.
Features include always present findings: Depression and Early chronotype.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Depression |
PER3 function has not been fully characterized.
Advanced sleep phase syndrome 3 is associated with mutations in the PER3 gene on chromosome 1.
Genetic testing for PER3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for advanced sleep phase syndrome 3 has been reported in the published literature.
Phenotype severity distribution: 2 always present features.
No clinical trials have been registered for advanced sleep phase syndrome 3.
217 publications have been identified in PubMed for advanced sleep phase syndrome 3. Kisho has analyzed 127 by research type. Research spans Epidemiology / Natural History (46%), Review / Meta-Analysis (29%), and Basic Science / Preclinical (10%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 58 | 46% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:41 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about advanced sleep phase syndrome 3
Research summaries |
37 |
29% |
Laboratory research | 13 | 10% |
Clinical study results | 11 | 9% |
New treatment approaches | 3 | 2% |
Testing and diagnosis research | 2 | 2% |
Patient case studies | 2 | 2% |
Other research | 1 | 1% |
Conti F (2026). [PMID: 40418260](https://pubmed.ncbi.nlm.nih.gov/40418260/). *Nutr Rev*. [Review / Meta-Analysis]
Bai WL (2026). [PMID: 41443528](https://pubmed.ncbi.nlm.nih.gov/41443528/). *Exp Eye Res*. [Basic Science / Preclinical]
Deshpande N (2026). [PMID: 41436011](https://pubmed.ncbi.nlm.nih.gov/41436011/). *J Affect Disord*. [Epidemiology / Natural History]
Donzella SM (2026). [PMID: 41546844](https://pubmed.ncbi.nlm.nih.gov/41546844/). *Cancer Causes Control*. [Epidemiology / Natural History]
Jääkallio P (2026). [PMID: 41371273](https://pubmed.ncbi.nlm.nih.gov/41371273/). *Pediatrics*. [Epidemiology / Natural History]
Adenan MH (2026). [PMID: 41526185](https://pubmed.ncbi.nlm.nih.gov/41526185/). *Pract Neurol*. [Review / Meta-Analysis]
Shea SA (2026). [PMID: 41500519](https://pubmed.ncbi.nlm.nih.gov/41500519/). *Physiol Rev*. [Review / Meta-Analysis]
Kang J (2026). [PMID: 41823621](https://pubmed.ncbi.nlm.nih.gov/41823621/). *Nurs Crit Care*. [Epidemiology / Natural History]
Fernandes-Campos G (2026). [PMID: 41420543](https://pubmed.ncbi.nlm.nih.gov/41420543/). *Epilepsia Open*. [Review / Meta-Analysis]
Kianersi S (2026). [PMID: 41603783](https://pubmed.ncbi.nlm.nih.gov/41603783/). *J Am Heart Assoc*. [Epidemiology / Natural History]